Analysts Set Expectations for NDRA FY2026 Earnings

ENDRA Life Sciences Inc. (NASDAQ:NDRA) – Research analysts at Ascendiant Capital Markets reduced their FY2026 earnings estimates for ENDRA Life Sciences in a research note issued to investors on Sunday, April 5th. Ascendiant Capital Markets analyst E. Woo now forecasts that the company will earn ($4.65) per share for the year, down from their previous forecast of ($4.62). The consensus estimate for ENDRA Life Sciences’ current full-year earnings is ($47.46) per share. Ascendiant Capital Markets also issued estimates for ENDRA Life Sciences’ Q4 2026 earnings at ($1.14) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of ENDRA Life Sciences in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $30.00.

ENDRA Life Sciences Trading Down 7.0%

Shares of NDRA opened at $4.94 on Friday. ENDRA Life Sciences has a 12 month low of $2.90 and a 12 month high of $11.96. The firm has a fifty day simple moving average of $3.91 and a 200 day simple moving average of $4.87. The stock has a market capitalization of $3.72 million, a price-to-earnings ratio of -0.55 and a beta of -0.23.

Institutional Investors Weigh In On ENDRA Life Sciences

An institutional investor recently bought a new position in ENDRA Life Sciences stock. Altium Capital Management LLC purchased a new position in shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences makes up about 0.9% of Altium Capital Management LLC’s holdings, making the stock its 17th biggest position. Altium Capital Management LLC owned approximately 6.92% of ENDRA Life Sciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.19% of the company’s stock.

About ENDRA Life Sciences

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.